Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 10;29(4):589-599.
doi: 10.53854/liim-2904-13. eCollection 2021.

Mortality and disability reported after immunoglobulins or plasmapheresis treatment of Guillain-Barré syndrome

Edinson Dante Meregildo-Rodriguez  1 , Victor Hugo Bardales-Zuta  2
Affiliations

Mortality and disability reported after immunoglobulins or plasmapheresis treatment of Guillain-Barré syndrome

Edinson Dante Meregildo-Rodriguez et al. Infez Med. .

Abstract

Objective: To compare the clinical results (28-day mortality and disability at discharge) in patients with Guillain-Barré Syndrome (GBS) treated with immunoglobulin or plasmapheresis at the Regional Lambayeque in Peru Hospital.

Patients and methods: Retrospective Cohort Study. Brighton criteria was used for diagnosing GBS, and modified Rankin scale (MRS) was employed for evaluating functional outcome. We used logistic regression for data analyses.

Results: A total of 142 cases of GBS diagnosed from 2011 to 2020 were included. GBS presented in a seasonal pattern; 60% of cases occurred in winter and spring. Motor variants (AMAN and AMSAN) accounted for 60% of cases, whereas only 8.5% of cases were typical GBS (AIDP). About 60% of patients were males, and 56% of cases corresponded to the age range of 20-59 years. Patients aged ≥60 years accounted for only 24% of total cases of GBS, but this group had a lethality of 58.3%. Although 28-day mortality was statistically similar in both treatment groups (plasmapheresis or immunoglobulin), we found a trend toward lower mortality in the plasmapheresis group (OR 0.78; 95% CI 0.62-0.97; p=0.062). We found no differences in terms of disability at discharge in GBS patients treated with plasmapheresis or immunoglobulin.

Conclusion: Mortality and functional outcome were statistically similar between patients treated with immunoglobulin or plasmatic exchange. However, there was a trend toward lower mortality in patients treated with plasmapheresis.

Keywords: Guillain-Barré syndrome; disability; mortality; therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest None to declare.

Figures

Figure 1
Figure 1
Frequency of cases of Guillain-Barré Syndrome (GBS) from 2011 to 2020, according to season and clinical form, Hospital Regional Lambayeque.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717–27. doi: 10.1016/S0140-6736(16)00339-1. - DOI - PubMed
    1. Malek E, Salameh J. Guillain-Barré Syndrome. Semin Neurol. 2019;39(5):589–95. doi: 10.1055/s-0039-1693005. - DOI - PubMed
    1. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–83. doi: 10.1038/s41582-019-0250-9. - DOI - PMC - PubMed
    1. Van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–82. doi: 10.1038/nrneurol.2014.121. - DOI - PubMed
    1. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27:S21–S24. doi: 10.1002/ana.410270707. - DOI - PubMed

LinkOut - more resources